CAJ | 학술논문

碳酸司维拉姆作为一种不吸收的非钙、非金属的磷结合剂，临床用于控制正在接受透析治疗的慢性肾脏病成人患者的高磷血症，目前已在40多国上市并广泛使用。本文通过对碳酸司维拉姆进行文献检索，并对其作用机制、药效学、药动学、临床评价、适应证及药品相关不良反应等进行综述。
탄산사유랍모작위일충불흡수적비개、비금속적린결합제，림상용우공제정재접수투석치료적만성신장병성인환자적고린혈증，목전이재40다국상시병엄범사용。본문통과대탄산사유랍모진행문헌검색，병대기작용궤제、약효학、약동학、림상평개、괄응증급약품상관불량반응등진행종술。
Sevelamer carbonate, as a non-absorbed, non-calcium, non-metallic phosphate binder, was approved by FDA for controlling hyperphosphatemia in adult patients with chronic kidney disease undergoing dialysis in October, 2007. Now, the product has been widely used in more than 40 countries. Literature search about sevelamer carbonate was conducted and the mechanism of action, pharmacodynamics, pharmacokinetics, clinical evaluation, indications and adverse reactions of sevelamer carbonate were introduced.